TOP MESSAGE 01
“Will My Eyes Get Better?”
After my internship, I returned to Japan to work as a clinical doctor at Kyushu University. One of my patients with age-related macular degeneration had been suffering from worsening sight due to changes in the macula, which is the most sensitive part of the retina.
As was the case then, there is still no fundamental cure for this disease. One day, this patient asked me: “Doctor, will my eyes get better? I’d like to be able to see my grandchild, who was born five years ago.” When I heard this earnest wish, I acutely felt my own powerlessness. It was then that I vowed to develop effective treatments and universally deliver them to patients, and this vow became my prime motivation for establishing Healios.
TOP MESSAGE 02
Success and Hardship in Starting a Business
*BBG is supported by 63.1 percent of ophthalmologists worldwide (excluding those in the US) according to a survey by the American Society of Cataract and Refractive Surgery.
However, unexpected drastic developments in the economic environment required changes in the company; at one point we had no choice but to severely downscale to a minimal number of personnel. We also had countless worries on the financial side. Thanks to the unfaltering support of our stakeholders, we were able to achieve results. This support allowed us to move forward while remaining true to our mission of developing effective treatments and delivering them to patients.
TOP MESSAGE 03
To Realize Our Original Mission
TOP MESSAGE 04
The Progress of iPSC Regenerative Medicine Products
The introduction of a new law targeting developments in regenerative medicine (the New Regenerative Medicine Law) represents a historic deregulation of Japan’s drug approval system, and is a global first.
Based on the efforts of many researchers over numerous years and the iPS cells developed by Dr. Shinya Yamanaka (for which he won the Nobel Prize in Medicine or Physiology), we would like to turn Healios into a major iPSC regenerative medicine product company. As a CEO, I would like to use the experience gained by overcoming a difficult period and channel it into cooperation with businesses, universities and research institutes to achieve our goal of delivering treatments to the patients who need them. At the same time, I would also like to pour all my energy into making safe and effective treatment methods using iPSC and somatic stem cell regenerative medicine products a reality.
You can watch the video of Chairman and CEO, Dr. Hardy TS Kagimoto presenting at GS 41st Annual Global Healthcare Conference Webcast（June 11, 2020）.
Please take a look, after pressing 『×』 in the upper right corner of the window.